This study planned to randomize approximately 450 patients
to one of five treatment arms to achieve a total of 425
evaluable patients. With 85 patients per group, the study had
80 % power to detect a 21 % difference in CR rate between the
rolapitant arm and placebo at an alpha=0.049 level of significance
(two-sided), assuming a placebo response rate of 50 %.
The primary analysis was based on all randomized patients
who received cisplatin-based chemotherapy and a dose of
study medication and had at least one post-treatment efficacy
assessment in cycle 1 recorded.